Medical Director

SARA M. MARIANI, M.D., M.S., Ph.D.

Home Address:

** ******** ******, ******* *****, CT - Cell Phone: 609-***-****

Email: **********@*****.*** or **********@*****.***

Business address:

The Scienomics Group / Healthcare Consultancy Group, Stamford Plaza 4,

Stamford, CT

Medical professional (Internal Medicine and Hem-Onc) with experience in:

Medical strategy, Drug development, Translational and clinical research,

Scientific/medical education & publications, Regulatory, Healthcare

communications

Major areas of expertise: Oncology and supportive care, Cancer biology,

Internal Medicine and CV, Hematology, Immunotherapy, Vaccines,

Transplantation, Rheumatology, Microbiology and infectious diseases,

Virology, Respiratory, Neurodegeneration (AD)

Date of birth: 8th August 1963; Place of birth: Milano, Italy

Marital Status: single; Citizenship: US citizen and EU (Italian) citizen

Languages

Bilingual, English and Italian

Good comprehension of written and spoken German

Comprehension of written French

Positions held

VP, Scientific Services, The Scienomics Group/TSG, Stamford, CT; and HSC,

New York, NY; Healthcare Consultancy Group (Omnicom)

July 2008- present

Group Medical Director, Medical Strategy and Communications, Inexel

(IHC/IPG)

Princeton P. Corporate Center, Lawrenceville, NJ

October 2007- July 2008

Medical Director, Medical Strategy and Communications, Interlink & Inexel

(IHC/IPG)

Princeton P. Corporate Center, Lawrenceville, NJ

March 2006- October 2007

Medical Director, CME Publications, Physicians Education Resource/Cancer

Information Group, Dallas, TX

2005-2006

Editorial Director, Medscape Molecular Medicine, and Pharmacotherapy, New

York, NY

Deputy Editor, Medscape General Medicine; Hematology-Oncology eSection

Editor

2002-2005

Editor & Program Director, Medscape Hematology-Oncology, New York, NY, US.

1999-2002

Research Editor, Nature Medicine, New York, NY

1998-1999

Research Editor, Nature, London, UK

1998

Guest Scientist, Dept. of Tumor Immunology, German Cancer Research Center,

Heidelberg, Germany

1993-1998

Postdoctoral Fellow, Dept. of Microbiology and Immunology, New York Medical

College, Valhalla, NY, USA

1988-1992

Fellow, Department of Internal Medicine, University Hospital S. Raffaele,

Milano, Italy

1984-1989

Fellow, Laboratory of Cellular Immunology and Immunotherapy, University

Hospital S. Raffaele, Milano, Italy

1986-1988

Fellow, Department of Pathology, Niguarda Hospital, Milano, Italy

1984-1985

Education

0. Italian National Boards in Hematology, cum laude

1988-1992 Specialty in Clinical Hematology (Hem-Onc), University of Pavia

Medical School, Italy

1991 Ph.D. in Microbiology and Immunology. GPA 3.9

1990 Master of Science in Microbiology and Immunology

1989-1991 Graduate School of Medical Sciences, New York Medical College,

Valhalla, NY

1989 Italian National Boards in Medicine and Surgery

1988 M.D. degree, cum laude

1984-1988 University of Milano, Medical School, Italy

1982-1984 University of Pavia, Medical School, Italy

1977-1982 Liceo Classico Carducci, Milano, Italy

Honors, Grants and Awards

1993-1995 European Community Research Grant, German Cancer Research

Center

1991-1992 Research grant from the Arthritis Foundation

1991-1992 Research grant from the Lupus Foundation of America

1991-1992 Postdoctoral Fellowship from the National Kidney Foundation

1990-1992 New York State Dept. of Health Research Award (Lyme Disease)

1990 Pat Santoro Research Grant from the Lupus Foundation of America

1989-1991 Postdoctoral Fellowship from the Juvenile Diabetes Research

Foundation

PROFESSIONAL EXPERIENCE

As Vice President of Scientific Services at the Scienomics Group/Health

Science Communications and as Group/Medical Director at Inexel/Interlink,

Medical Strategy and Communications:

-Directed and/or contributed to the development of medical education

initiatives/programs, scientific platforms, publication plans, scientific

events, symposia, conference presentations, advisory boards, promotional

programs, label development, pipeline and franchise analyses, competitive

intelligence, strategic reports.

-Worked with pharmaceutical & biotech clients (medical affairs, discovery,

clinical research, marketing, regulatory, legal) (US and global) on

multiple compounds/brands and pipelines.

-Selected, supervised, and/or directed associate/medical directors (MD MPH,

PhD, MD), senior/ medical writers (PhD, DO)

As Medical Director for the Physicians Education Resource / Cancer

Information Group:

-Reviewed/edited oncology CME programs and other publications for clinical

content and presentation, to ensure release of medically/scientifically

accurate, relevant, and cutting edge information for physicians and other

healthcare professionals

-Assessed and refined goals and objectives of oncology programs and

publications. Provided input on proposals for clinical/scientific accuracy

and value

-Directed and mentored the medical writing team (PhDs)

As Deputy Editor and Editorial/Program Director for Medscape:

-Managed medical specialty web sites with professional and lay audience

-Directed senior/clinical editors, assistant and associate editors,

editorial assistants,

-Selected and directed medical writers and freelancing contributors (MD,

PhD, MS, RN)

-Maintained close collaborations with production, IT, marketing and sales

teams

-Prepared budgets and managed funds available to the specialty sites

EDITORIAL experience

- Deputy Editor Medscape General Medicine, and Hematology-Oncology eSection

Editor

- Site Editor & Program Director, Medscape Molecular Medicine, Urology,

Pharmacotherapy

- Site Editor & Program Director, Medscape Hematology-Oncology

- Research Editor, Nature and Nature Medicine

As Editorial Director/Site Editor and Program Director for Medscape

- Evaluated clinical and research content for novelty, value to the

specialty, and fairness. Established and maintained a strong editorial

board composed of recognized thought leaders in the field.

- Maintained site content relevant, compelling, up to date. Studied

information needs of clinicians and researchers in the specialty, and

helped to develop and refine high-value resources for the specialty site.

Developed programs offered for Continuing Medical Education.

- Solicited and developed online interactive programs, monographs, updates

and additional editorial resources and features. Organized and supervised

online coverage of key specialty meetings. Managed peer review process for

content development. Written and edited for a physician/researcher

specialty audience.

- Coordinated with marketing and sales team on new features, refinements,

professional meetings. Represented Medscape Editorial to professional

organizations, physicians, researchers, media, and sponsors.

As Research Editor for Nature Medicine and Nature:

- Manuscript selection for Nature Medicine and Nature

Areas covered: all areas of interest to Nature Medicine, with particular

interest in:

Immunology, autoimmune diseases, immunotherapy, immunomodulation, vaccines,

hematology, oncology, clinical studies and clinical trials, new drugs,

transplantation, malaria, HIV, and virology

- Organization and management of peer review process

- Commission, review and edit of News and Views articles, Commentaries and

Reviews

- Writing of editorial pieces

- Conference attendance

- Maintenance of close collaboration with production editors, marketing and

advertising teams

- Participation in Web development

Peer review

1994-2005. Peer reviewer for Cancer Res, J Immunol, Eur J Immunol, J Cell

Biol, J Exp Med, Clin Cancer Res and other journals.

RESEARCH experience

- Performed mentor-supervised and then independent research in molecular

and cellular immunology, clinical immunology, cancer biology and cell

biology.

- Broad experience in cellular, biochemical and molecular techniques. Hands-

on work at the bench for more than 10 years, in collaboration with

colleagues, students, and technicians.

Specific research projects:

1993-1998 Apoptosis and cancer. Tumor-mediated immunosuppression.

Apoptosis, Fas, TRAIL and immune homeostasis. Molecular mechanisms

of thymic selection. Apoptosis in liver diseases and H. pilori

infection.

1988-1992 Histocompatibility. Pathogenesis of renal allograft rejection.

Immunotherapy of autoimmune diseases.

1986-1988 Modulation of T- and NK-cell effector functions. Lymphokine-

mediated cancer therapy.

- Please find enclosed list of Publications stemming from these research

projects.

- Participation and presentation of poster and oral communications to North

American and International scientific meetings.

DIRECTION, TEACHING, AND SUPERVISORY experience

. Supervision and/or direction of associate/medical directors, senior/

medical writers (Interlink/Inexel, IHC)

. Supervisor and mentor, medical writers' team (PER/CIG)

. Supervision of master and graduate students' research and theses (German

Cancer Research Center).

. Technical training of master and graduate students, medical students and

junior postdoctoral fellows (New York Medical College and German Cancer

Research Center).

. Instructor, Medical Microbiology Laboratories (New York Medical College).

CLINICAL experience

1989-1992

Department of Internal Medicine/Hematology, University Hospital San Matteo,

Pavia, Italy

1985-1989

Department of Internal Medicine, University Hospital San Raffaele, Milano,

Italy.

Ward and ambulatory - Broad Internal Medicine training/practice with

particular focus on oncology, hematology, GI, pulmonary, and autoimmune

disease patients

1984-1985 Department of Pathology, Niguarda Hospital, Milano, Italy

Selected Conferences attended in the past few years - Annual Meetings

2004-2010

American Society of Clinical Oncology

American Society of Hematology

Chemotherapy Foundation Symposium

American College of Rheumatology

World Transplantation Congress

Drug Discovery Technology World Congress

American Association for Cancer Research

First Intl. Conference Complementary Oncology

American Society of Human Genetics

American Society of Gene Therapy

Intl. Meeting Alzheimer Disease

American Society of Cell Biology

Integrating Technologies in Proteomics and Genomics

Multiple advisory boards

Multiple CME Symposia

Scientific Symposia

2000-2003

American Society of Clinical Oncology

American Society of Hematology

European Society of Medical Oncology

San Antonio Breast Cancer Conference

American Association for Cancer Research

American Society of Clinical Pathology

American Society for Clinical Laboratory Sciences

American Association of Immunologists

American Society of Cell Biology

Society for Neuroscience

Keystone Conference on Systems Biology

PUBLICATIONS

Research Articles

Strater J*, Mariani SM*, Walczak H*, Rucker FG, Leithauser F, Krammer PH,

Moller P. CD95 ligand (CD95L) in normal human lymphoid tissues: a subset of

plasma cells are prominent producers of CD95L. Am J Pathol 1999 154: 193-

201

Mariani SM, Krammer PH. Surface expression of TRAIL/Apo-2 ligand in

activated mouse T and B cells. Eur J Immunol 1998 285: 1492-1498

Strand S, Hofmann WJ, Grambihler A, Hug H, Volkmann M, Otto G, Wesch H,

Mariani SM, Hack V, Stremmel W, Krammer PH, Galle PR. Hepatic failure and

liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas)

mediated apoptosis. Nature Med 1998 4: 588-593

Rudi J, Kuck D, Strand S, von Herbay A, Mariani SM, Krammer PH, Galle PR,

Stremmel W. Involvement of the CD95 (APO-1/Fas) receptor and ligand system

in Helicobacter pylori-induced gastric epithelial apoptosis. J Clin Invest

1998 102:1506-1514

Mariani SM, Krammer PH. Differential regulation of TRAIL and CD95 ligand in

transformed cells of the T and B lymphocyte lineage. Eur J Immunol 1998 28:

973-982

Mariani SM, Krammer PH. Detection of active infection of Sf9 insect cells

by recombinant baculoviruses. J Virol Methods 1997 69:19-28

Mariani SM, Matiba B, Armandola EA, Krammer PH. Interleukin 1 beta-

converting enzyme related proteases/caspases are involved in TRAIL-induced

apoptosis of myeloma and leukemia cells. J Cell Biol 1997 137: 221-229

Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM,

Stremmel W, Krammer PH, Galle PR. Lymphocyte apoptosis induced by CD95 (APO-

1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion? Nature

Med 1996 2: 1361-1366

Mariani SM*, Matiba B*, Sparna T, Krammer PH. Expression of biologically

active mouse and human CD95/APO-1/Fas ligand in the baculovirus system. J

Immunol Methods 1996 193: 63-70

Muller KP*, Mariani SM*, Matiba B, Kyewski B, Krammer PH. Clonal deletion

of major histocompatibility complex class I-restricted CD4+CD8+ thymocytes

in vitro is independent of the CD95 (APO-1/Fas) ligand. Eur J Immunol 1995

25: 2996-2999

Mariani SM, Matiba B, Baumler C, Krammer PH. Regulation of cell surface APO-

1/Fas (CD95) ligand expression by metalloproteases. Eur J Immunol 1995 25:

2303-2307

Rensing-Ehl A, Frei K, Flury R, Matiba B, Mariani SM, Weller M, Aebischer

P, Krammer PH, Fontana A. Local Fas/APO-1 (CD95) ligand-mediated tumor cell

killing in vivo. Eur J Immunol 1995 25: 2253-2258

Mariani SM, Matiba B, Armandola EA, Krammer PH. The APO-1/Fas (CD95)

receptor is expressed in homozygous MRL/lpr mice. Eur J Immunol 1994 24:

3119-3123

Mariani SM, Armandola EA, Ferrone S. Preferential selection of a subset of

anti-HLA-DR monoclonal antibodies by a syngeneic antiidiotypic monoclonal

antibody. Transplantation 1993 55: 1176-1181

Armandola EA, Mariani SM, Ferrone S. Serological and molecular

characterization of mouse anti-idiotypic monoclonal antibodies elicited

with the syngeneic anti-HLA-A2,28 monoclonal antibody CR11-351. Mol Immunol

1993 30: 287-300

Mariani SM, Armandola EA, Ferrone S. Diversity of anti-HLA-DR antibodies

elicited by distinct anti-idiotypic monoclonal antibodies recognizing

idiotopes co-expressed by the immunizing monoclonal antibody. Immunology

1992 77: 597-603

Mariani SM, Armandola EA, Ferrone S. Heterogeneity in the anti-HLA-DR

immune response elicited by the antiidiotypic monoclonal antibody F5-444.

Analysis at the clonal level. Transplantation 1992 54: 1078-1084

Armandola EA, Mariani SM, Zwickl M, Hardman N, Ferrone S. Molecular

analysis of anti-idiotypic monoclonal antibodies in the HLA-DR antigenic

system. Eur J Immunol 1992 22: 2893-2899

Mariani SM, Armandola EA, Ferrone S. Diversity in the fine specificity and

idiotypic profile of mouse anti-HLA-DR monoclonal antibody elicited with

the syngeneic anti-idiotypic monoclonal antibody F5-830. J Immunol 1991

147: 1322-1330

Mariani SM, Armandola EA, Ferrone S. Diversity in the fine specificity of

anti-HLA-DR monoclonal antibodies elicited with syngeneic antiidiotypic

monoclonal antibodies. Transplant Proc 1991 23: 455-456

Zocchi MR, Poggi A, Mariani S, Gianazza E, Rugarli C. Identification of a

new surface molecule expressed by human LGL and LAK cells. Production of a

specific monoclonal antibody and comparison with other NK/LAK markers.

Cell. Immunol. 1989 124: 144-157

Reviews

Matiba B, Mariani SM, Krammer PH. The CD95 system and the death of a

lymphocyte. Semin Immunol 1997 9: 59-68

Mariani SM, Matiba B, Krammer PH. CD95 (APO-1/Fas) and its ligand in the

mouse immune system. Behring Inst Mitt 1996 97: 12-23

Krammer PH, Dhein J, Walczak H, Behrmann I, Mariani S, Matiba B, Fath M,

Daniel PT, Knipping E, Westendorp MO, et al. The role of APO-1-mediated

apoptosis in the immune system. Immunol Rev 1994 142: 175-191

Selected Scientific Presentations at International Conferences and Meetings

- EMBO Worshop on cell-mediated cytotoxicity, Kerkrade, The Netherlands,

1997

Mariani SM, Matiba B, Armandola EA and Krammer PH. Involvement of caspases

in TRAIL-induced apoptosis.

- Workshop on proliferation, differentiation and death in human skin,

Salzburg, Austria, 1996

Invited lecture: The APO1-Fas/CD95 system

- 8th International H-2/HLA Worshop, Jekyl Island, Georgia, 1992

Armandola E, Mariani SM, Zwickl M, Hardman N, and Ferrone S. Molecular

basis of HLA-DR recognition by antiidiotypic monoclonal antibodies.

- 11th International Histocompatibility Workshop and Conference, Yokohama,

Japan, 1991

Mariani SM, Armandola E, and Ferrone S. Heterogeneity in the anti HLA-DR

immune response elicited by the antiidiotypic monoclonal antibody F5-444.

Analysis at the clonal level. PS-D-19.

- XIII International Congress of the Transplantation Society, San

Francisco, California, 1990

Mariani S, Armandola E, Wang J and Ferrone S. Specificity and idiotype

diversity of murine anti-HLA DR monoclonal antibodies elicited with the

syngeneic antiidiotypic monoclonal antibody F5-830.

- FASEB Meeting, New Orleans, Louisiana, 1989

Mariani SM, Armandola E, Castello G and Ferrone S. Molecular

characterization of syngeneic monoclonal antiidiotypic antibodies to the

anti HLA-A2,28 monoclonal antibody CR11-351. Fed Proc. A793:3292 (1989)

Armandola E, Mariani SM, and Ferrone S. Molecular diversity in the

antiidiotypic response to anti-HLA Class II antibodies. Fed. Proc.

A520:1713 (1989)

Selected Articles, Reports, and Commentaries - 2003/2004 - Sara M Mariani

Medline-Indexed Medscape General Medicine eJournal

- Oncology

CME - Early Cancer Diagnosis- Beating the Odds

Targeting Cancer Cells-More Pathways, More Inhibitors, More Trials

Anti-Angiogenesis Cocktails

Lung Cancer and Gene Therapy

At the Forefront of Cancer Research-Clinical Results

Phytoestrogens and Cancer-Bits of Experimental Evidence

Dangerous liaisons-Infections and Cancer

- Drug Discovery

The Long Road from Discovery to Clinic

Translational research: Any dangers lurking in its wake?

Functional Genomics: Improving Cancer Prognosis and Drug Development.

- Cancer Biology & Cancer Research

Cancer Research 2004-Top of the Class

At the Forefront of Cancer Research- Preclinical Data

Extracellular Matrix: Revisiting Metalloproteinases

Tumor-Host Interactions: A Complex Network of Signals

Apoptosis: A Graceful Death

From genes to cells to metastasis

Cancer and The Immune System: Improving The Odds

- Immunology and Autoimmune Diseases

Dendritic Cells: Myths and Reality

Novel Therapies for Systemic Lupus Erythematosus?

Lupus Nephritis-Diagnosis, Therapy and Outcomes

Silencing Autoimmunity in Multiple Sclerosis, Lupus and Rheumatoid

Arhtritis

- Pathology, Molecular Diagnostics & Transfusion Medicine

Breast Cancer Markers: What Next?

Magic Markers for the Diagnosis of Thyroid Carcinomas?

Clinical Pathology: The Top 5 Studies of the Journal

Transfusions and TRALI: What Are The Risks Today?

- Genomics, Proteomics and Molecular Biology

Protein Microarrays in Cancer and Autoimmunity: Tiny spots light up

Genomics: The Promise of SNPs and Bats

Structural Genomics: Parsing the Architecture of Proteins

Engineering Proteins: Interferon, Diphtheria toxin, and Growth Hormone

Clinical Proteomics: New Promises for Early Cancer Detection

- Human Genetics, Gene Therapy & Tissue Engineering

CME - Genes and Autoimmunity-A Complex Inheritance

Gene Therapy-Quality Matters

Gene Therapy and Tissue Engineering

Severe Immunodeficiencies: BMT or Gene Therapy?

Contact this candidate